menu
    • menu
    [{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Allergan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cenicriviroc","moa":"C-C chemokine receptor type 2 | C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Charite University, Berlin, Germany \/ Allergan","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Allergan"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Infliximab","moa":"||TNF-alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"National Institutes of Health \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Cenicriviroc

    Menu

    Cenicriviroc

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            National Institutes of Health

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed

                            National Institutes of Health

                            U.S.A arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Infliximab,Abatacept,Cenicriviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NIH Begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19

                            Details : The three drugs are Janssen’s infliximab (Remicade), Bristol Myers Squibb’s (BMS) abatacept (Orencia) and AbbVie’s investigational late-stage drug Cenicriviroc (CVC).

                            Product Name : Remicade

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            October 16, 2020

                            Lead Product(s) : Infliximab,Abatacept,Cenicriviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Charite University, Berlin, Germany

                            Country arrow
                            The MedTech Conference
                            Not Confirmed

                            Charite University, Berlin, Germany

                            Country arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cenicriviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Allergan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients

                            Details : Cenicriviroc is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 05, 2020

                            Lead Product(s) : Cenicriviroc

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Allergan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth